Cornerstone Pharmaceuticals Initiates Phase I Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non-Hodgkin's Lymphoma

CRANBURY, N.J., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial of CPI-613, in combination with bendamustine (Treanda), for patients with relapsed or refractory classic Hodgkin's lymphoma or T-cell non-Hodgkin's lymphoma who may or may not have received hematopoietic cell transplant. CPI-613 is the company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, designed to disrupt the altered energy-production pathways in cancer cells.

Non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) are two common types of cancers of the lymphatic system, part of the immune system, that compromise the body's ability to fight infections. Classic Hodgkin's lymphoma is the more common type of HL, with approximately 95 percent of cases considered to be classic HL. There are projected to be approximately 70,000 new cases of NHL, with close to 19,000 deaths, and over 9,000 new cases of HL, with approximately 1,200 deaths, in the United States during 2014.

The single site study, sponsored by Wake Forest Baptist Medical Center and in collaboration with the National Cancer Institute (NCI), is a Phase I, open label, dose-escalating study designed to establish the maximum tolerated dose of CPI-613 when used in combination with bendamustine. Response and overall survival rates will also be measured in this study. Bendamustine has shown single agent activity in the relapsed lymphoma setting with response rates of approximately 50 percent for B and T-cell NHL as well as in classic HL. The study will include patients with relapsed or refractory classic HL or T-cell NHL who may or may not have received hematopoietic cell transplant.

Robert Rodriguez, Cornerstone's President and Chief Operating Officer, said, "This clinical trial is a key milestone for Cornerstone, further demonstrating the potential applicability of our lead product candidate, CPI-613, in these types of hematologic malignancies, and the first study to examine the drug in the classic Hodgkin's or T-cell non-Hodgkin's lymphoma-specific patient population when combined with bendamustine. We look forward to working with the investigators at Wake Forest Baptist Medical Center on this study as we continue to explore the use of our AEMD approach in the treatment of a wide array of cancers."

Zanetta Lamar, MD, of Wake Forest Baptist Medical Center and the Principal Investigator for the trial, remarked, "Relapsed and refractory lymphomas can be extremely debilitating. The long-term survival rate for the majority of these patients is low, and the impact on the ability of the immune system to stave off disease and infection creates further complications. We hope that utilizing CPI-613 in conjunction with bendamustine has the potential to offer a beneficial alternative for the treatment of classic HL and T-cell NHL patients."

CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone's AEMD drug platform disrupts the essential "bioenergetic" differences that support the growth and development of many types of cancer cells. In the case of CPI-613, the compound has been shown to selectively induce inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in cancer cell metabolism in-vitro. Disruption of PDH and KGDH function cuts off the tumor's energy supply, culminating in cell death. CPI- 613 is currently being evaluated in Phase I, I/II and II human clinical trials in solid tumors and hematological malignancies.

About Wake Forest Baptist Medical Center

Wake Forest Baptist Medical Center ( wakehealth.edu ) is a fully integrated academic medical center located in Winston-Salem, N.C. The institution comprises Wake Forest School of Medicine , a leading center for medical education and research; Wake Forest Baptist Health , the integrated clinical structure that includes nationally ranked Brenner Children's Hospital ; Wake Forest Innovations , which promotes the commercialization of research discoveries and operates Wake Forest Innovation Quarter , an urban research and technology park; plus a network of affiliated community hospitals, physician practices, outpatient services and other medical facilities. Wake Forest Baptist clinical programs and the School of Medicine are regularly ranked among the best in the country by U.S. News & World Report.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two distinct technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphan lipid nanoemulsion based drug delivery system. www.cornerstonepharma.com .

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Investor Contacts: David Burke The Ruth Group (646) 536-7009 Media Contact: Kirsten Thomas The Ruth Group (646) 536-7014 Marguerite Beck Senior Manager, National Media Relations Wake Forest Baptist Medical Center (336) 716-2415; (fax) 336-716-6841

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 81

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Scalefusion’s Platinum Win Sharpens Its Brand Story

Updated Category News Views 14

A Film Is Not a Balance Sheet A slick brand film cannot patch a leaky product, but it can make a complicated platform easier to remember. That is the sensible takeaway from Scalefusion’s Platinum Level win at the 2026 MarCom Awards for “One Platform. One Agent. We are Scalefusion.” The recognition is for creative execution, not commercial performance, and anybody...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 88

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 194

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 80

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 165

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading

Top 5 Most Recently Viewed Articles

Foresight Autonomous Holdings Reports 2024 Financial Outcomes

Updated Category News Views 231

Financial Overview of Foresight Autonomous Holdings Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) has recently disclosed its financial results for the fourth quarter and overall year of 2024. The company, known for its groundbreaking 3D perception systems, reported annual revenues of $436,000. By the end of the year, it held $7.2 million in cash and equivalents,...

Continue Reading
Imperial Metals Showcases Remarkable First Quarter Growth

Updated Category News Views 156

Imperial Metals Demonstrates Strong Performance in First Quarter Imperial Metals Corporation (TSX:III) has revealed its financial results for the first quarter of 2025, showcasing remarkable growth in production and revenue. The company aims to maintain a trajectory of operational efficiency and profitability, continuing its commitment to sustainable mining practices. Key...

Continue Reading
MOBILion Systems Redefines Mass Spectrometry in Proteomics

Updated Category News Views 144

A New Era for Mass-Spectrometry-Based Proteomics In a groundbreaking achievement, MOBILion Systems has demonstrated a remarkable technical milestone, fundamentally changing mass-spectrometry-based proteomics. The company's proof-of-concept for high-resolution ion mobility (HRIM) showcases its innovative PAMAF mode, setting a new standard for efficient and effective...

Continue Reading
Celebrating Excellence: FASTSIGNS Honors Top Vendors for 2024

Updated Category News Views 316

FASTSIGNS International Celebrates Outstanding Vendors Grimco and Spicers Recognized for Exceptional Supplier Relationship FASTSIGNS®, a leading name in custom signs and visual solutions, recently honored Grimco as the U.S. Vendor of the Year and Spicers as the Canadian Vendor of the Year during the 2025 FASTSIGNS International Convention. The event took place in a...

Continue Reading
Insights into Central Government's 2026 Borrowing Plans

Updated Category News Views 116

Overview of the Central Government's Borrowing Strategy The update regarding the central government's borrowing strategy for 2026 has been officially released, providing crucial insights into the planned financial activities for the period. This detailed plan outlines essential objectives and anticipated actions that aim to enhance the overall stability of the economy....

Continue Reading